Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 3Thoracic 2Sarcoma 2Plasma cell 2Lymphoid 2Other hematologic neoplasm 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 28Leukemia 27Anemia, Refractory, with Excess of Blasts 26Leukemia, Myeloid, Acute 24Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Leukemia, Myelomonocytic, Chronic 19Leukemia, Myeloid, Chronic-Phase 17Leukemia, Myeloid, Accelerated Phase 17Myeloproliferative Disorders 16Lymphoma 16Lymphoma, Non-Hodgkin 14Leukemia, Lymphocytic, Chronic, B-Cell 14Congenital Abnormalities 13Burkitt Lymphoma 13Blast Crisis 13Hodgkin Disease 12Primary Myelofibrosis 11Multiple Myeloma 11Lymphoma, Mantle-Cell 11Lymphoma, Large-Cell, Immunoblastic 11Lymphoma, Follicular 11Myelodysplastic-Myeloproliferative Diseases 10Lymphoma, Large B-Cell, Diffuse 10Anemia, Refractory 10Lymphoma, B-Cell, Marginal Zone 9Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 9Neoplasms, Plasma Cell 8Dendritic Cell Sarcoma, Interdigitating 8Recurrence 6Neutropenia 6

Interventions

pegfilgrastim 2Epoetin Alfa 2Cisplatin 2sodium thiosulfate 1etoposide phosphate 1Rituximab 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Erythropoietin 1Docetaxel 1Darbepoetin alfa 1Cytarabine 1Cyclophosphamide 1Carboplatin 1Brachytherapy 12,2'-dithiodiethanesulfonic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Filgrastim × Classical hematology × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡